ClinicalTrials.gg
RecruitingNCT06006117Updated Jun 15, 2026

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

A Phase 3 interventional study of Mosunetuzumab (SC) and Rituximab (R) in Marginal Zone Lymphoma, sponsored by The Lymphoma Academic Research Organisation. Recruiting at 48 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by The Lymphoma Academic Research Organisation · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 30 studies testing lenalidomide in Lymphoma, B-Cell, Marginal Zone — 5 open to participants now, 7 under way, 1 of them phase 3. Lenalidomide · Lymphoma, B-Cell, Marginal Zone.

Planned enrollment
2nd of 29
260 · median 36
Started
2023
the only one that year
Phase 3
2 of 30
1 open now
Registered
28th of 30
by date

Among the 30 studies testing lenalidomide in Lymphoma, B-Cell, Marginal Zone, this one is the 2nd largest by planned enrollment of the 29 interventional ones that give a count, is the only one that started in 2023, is one of 2 in phase 3, and was the 28th registered.

Lymphoma, B-Cell, Marginal Zone

877 studies on the registry are indexed under Lymphoma, B-Cell, Marginal Zone; 113 are open to participants now.

Browse Lymphoma, B-Cell, Marginal Zone studies →

Open to participants now

5 of the 30 studies testing lenalidomide in Lymphoma, B-Cell, Marginal Zone are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 93 Lymphoma, B-Cell, Marginal Zone studies recruiting now, 78 (84%) set no upper age limit and 7 (8%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing lenalidomide in Lymphoma, B-Cell, Marginal Zone, or all of them as a file.
02

Study summary

This is an open label, multi-center, international, randomized phase III trial to compare the efficacy of Mosunetuzumab-Lenalidomide with investigator choices exclusively in R/R MZL patients. Patients with a proven diagnosis of EMZL, SMZL or NMZL subtypes and previously treated with at least one prior systemic treatment and not more than three prior lines are eligible. Previous treatment line must include at least one systemic line with a drug targeting CD20 (monoclonal antibody at least 2 cycles) with or without chemotherapy (R-CHOP, R-Bendamustine, R-CVP, R-Chlorambucil at least 2 cycles) or targeted treatment such as Ibrutinib.

The patients will be Randomized as follows:

Arm A - Experimental arm:

  • Mosunetuzumab-Lenalidomide

Arm B - Comparator arms ( Investigator Choices):

  • Rituximab-Lenalidomide
  • Rituximab-Bendamustine
  • Rituximab-CHOP
Read the detailed description

This is an open label, multi-center, international, randomized phase III trial to compare the efficacy of Mosunetuzumab-Lenalidomide with investigator choices exclusively in R/R MZL patients. Patients with a proven diagnosis of EMZL, SMZL or NMZL subtypes and previously treated with at least one prior systemic treatment and not more than three prior lines are eligible. Previous treatment line must include at least one systemic line with a drug targeting CD20 (monoclonal antibody at least 2 cycles) with or without chemotherapy (R-CHOP, R-Bendamustine, R-CVP, R-Chlorambucil at least 2 cycles) or targeted treatment such as Ibrutinib.

Patients are stratified according to MZL subtypes and time to progression of disease after first-line within 2 years (POD24) \< 2 years or > 2 years.

Mosunetuzumab will be administered sub-cutaneously (SC) (21 days first cycle, then 28 days next cycles) and Lenalidomide will be given PO 20 mg/day from Day 1 to Day 21 from cycles C2 to C6. For each patient, investigator choice had to be decided before randomization between Rituximab-Lenalidomide and Rituximab-chemotherapy (R-Bendamustine or R-CHOP).

The primary efficacy endpoint for comparison is the Progression-free survival (PFS) as determined by investigator (Lugano criteria 2014). Secondary objectives include CR24 as determined by investigator (at 24 months) according to Lugano criteria 2014 and by central review based on PET result, Overall response rate (ORR) and CR other than CR24 as determined by investigator, or by central review based on PET result according to Lugano Criteria 2014. 260 patients are planned to be enrolled in France, Belgium, Germany, Italy and Portugal

03

Conditions studied

  • Marginal Zone Lymphoma

Keywords

  • Bispecific antibodies, Subcutaneous
  • Step-up dosing
  • Marginal Zone Lymphoma
  • Investigator choices
  • R/R MZL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have a proven diagnosis of MZL, extranodal (EMZL) or nodal (NMZL) Or have a diagnosis of splenic MZL (SMZL) based on mandatory 13 flow cytometry markers: surface immunoglobulins (SmIg), CD5, CD23, FMC7, CD22 or CD79b, CD200, CD180, CD20, 3, CD11c, CD10,CD103 and CD123 and validated by a centralized review.

    In case of large dissemination, disseminated MZL (as evaluated by investigator; please contact the Sponsor to discuss any doubt) will be included as DMZL and included in NMZL subtype. Participants with high tumor burden criteria are eligible.

    Participants with borderline or related entities, such as splenic diffuse red pulp lymphoma (SDRPL), typical hairy cell leukemia (HCL), and HCL variant (HCLv), are not eligible.

  2. Have been treated with at least one prior systemic treatment and not more than three prior lines. Previous line must include at least one systemic line with a drug targeting CD20 (monoclonal antibody at least 2 cycles; participants treated with monoclonal antibody monotherapy should have received at least 4 weekly injections) with or without chemotherapy (R-CHOP, R-Bendamustine, R-CVP, R-Chlorambucil at least 2 cycles) or targeted treatment such as BTK inhibitors (at least 1 month). Participants previously treated by lenalidomide are eligible if the last administration of lenalidomide is superior to 12 months before C1D1. When randomized in comparator arm, those participants should require R-chemo. Prior local therapy (including surgery, radiotherapy antibiotics for H. pylori-positive gastric lymphoma, and antiviral for virus) is not considered as one
  3. Signed Form
  4. Age ≥ 18 years at the time of signing the informed consent form
  5. Ability to comply with the study protocol and procedures and required hospitalizations, in the investigator's judgement
  6. (ECOG) performance score (PS) of ≤ 2
  7. Have a symptomatic disease requiring a systemic treatment
  8. Not eligible for a local treatment including radiotherapy or surgery
  9. Stage I disease of EMZL, SMZL or NMZL may be eligible only if not candidate to local therapy (surgery or radiotherapy).
  10. in at least two perpendicular dimensions on an imaging scan is defined as: lymph node or nodal mass bi-dimensional measurement with ≥ 15 mm in longest transverse diameter or the short diameter must measure ≥ 10 mm regardless of the longest transverse diameter.

    Spleen is considered as a measurable disease if vertical axis is higher than 130 mm.

  11. Adequate hematopoietic function at screening as follows unless cytopenia is clearly due to marrow involvement of MZL or hypersplenism or thrombocytopenia:

    11.1. count ≥ 75 G/L; in cases of thrombocytopenia clearly due to marrow involvement of MZL or hypersplenism or auto-immune thrombocytopenia, platelet count should be ≥ 30 G/L. Washout platelet transfusion is 7 days between transfusion and D1 of starting treatment 11.2. (ANC) ≥ 1 G/L unless neutropenia is clearly due to marrow involvement of MZL or hypersplenism. G-CSF is not allowed within 7 days before starting treatment 11.3. Total ≥ 8 g/dL unless anemia is clearly due to marrow involvement of MZL or hypersplenism or autoimmune hemolytic anemia. Washout erythrocyte transfusion is 7 days between transfusion and D1 of starting treatment

  12. Serum total ≤ 1.5 x the (ULN) (or ≤3 x ULN for participants with Gilbert syndrome),
  13. or ALT ≤ 2.5 x ULN, unless directly attributable to the participant's MZL
  14. Measured or estimated ≥ 40 mL/min by institutional standard method
  15. Participants who are surface antigen (HBsAg) negative and hepatitis B core antibody (HBcAb) positive, must be negative for hepatitis B virus (HBV) polymerase chain reaction (PCR) to be eligible for study participation. Participants who are hepatitis B surface antigen (HBsAg) negative, hepatitis B surface antibody (anti-HBsAb) positive and hepatitis B core antibody (HBcAb) negative are eligible,
  16. :

    16.1. For women of (WOCBP) (refer to section 14.6.1):

    • must have a negative result for pregnancy test (highly sensitive serum) within 7 days before randomization and within 7 days before initiation of study treatment.
    • must agree to abstain from becoming pregnant or breastfeeding, and agree to use highly effective contraceptive methods during study participation, and for at least 28 days after the final dose of lenalidomide (if applicable), 3 months after the final dose of mosunetuzumab and tocilizumab (if applicable), 12 months after the final dose of CHOP (if applicable), 6 months after the final dose of bendamustine (if applicable) and 12 months after the final dose of rituximab (if applicable).

    16.2. For men: with a female partner of childbearing potential or pregnant female partner, men must remain abstinent or use a condom during the treatment period (including periods of treatment interruption), and for at least 28 days after the final dose of lenalidomide (if applicable), 2 months after the final dose of tocilizumab (if applicable), 6 months after the final dose of CHOP (if applicable), 3 months after the final dose of bendamustine and 12 months after the final dose of rituximab (if applicable). ). Men must also agree to refrain from donating sperm from the first day of treatment until at least 7 days after the final dose of lenalidomide (if applicable), 2 months after the final dose of tocilizumab (if applicable), 6 months after the final dose of CHOP (if applicable), 3 months after the final dose of bendamustine (if applicable), and 12 months after the final dose of rituximab (if applicable)

  17. Participants covered by any social security system (France).
  18. Participants who understand and speak one of the country official languages.
  19. within normal range (i.e. > 50% as evaluated by Transthoracic Echocardiography or > 45% as evaluated by isotopic method (MUGA scan)).

Exclusion criteria

Exclusion criteria:

  1. MZL with histologic transformation to high-grade lymphoma
  2. Participants who have received any of the following treatments prior to study entry:

    • Treatment with mosunetuzumab or other CD20/CD3-directed bispecific antibodies
    • stem cell transplant
  3. Participants who have received any of the following treatments, whether or approved, within the respective time periods prior to initiation of study treatment:

    • Radiotherapy within 2 weeks prior to the first dose of study treatment
    • Autologous stem cell transplant within 100 days prior to first study treatment
    • Use of monoclonal antibodies within 4 weeks prior to first study treatment
    • Systemic medications (including, but not limited to, Cyclophosphamide, Azathioprine, Methotrexate, Thalidomide, and anti-tumor necrosis factor agents) and on the long run with the following exceptions: inhaled steroids for asthma, topical steroids, or replacement or stress corticosteroids during the study at any time. Participants who require lymphoma symptom control during screening may receive corticosteroid \< or = 1mg/kg/day prednisone or equivalent for a maximum of 10 days prior to first dose of study treatment.
    • Any other anti-cancer investigational therapy within 4 weeks prior to initiation of study treatment.
  4. Pregnant or breastfeeding or intending to become pregnant during the study or within 28 days after the final dose of lenalidomide, 3 months after the final dose of mosunetuzumab and tocilizumab (if applicable), 12 months after the final dose of CHOP, 6 months after the final dose of bendamustine and 12 months after the final dose of rituximab (if applicable).
  5. Received a live, attenuated vaccine within 4 weeks before first dose of study treatment, or in whom it is anticipated that such a will be required during the study period or within 6 months after the final dose of study treatment, except for acute pandemic situation such as COVID19
  6. Active or history of CNS lymphoma or infiltration
  7. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibody therapy (or recombinant antibody-related fusion proteins) - grade 3 and 4
  8. Known to biopharmaceuticals produced in CHO cells or any component of the mosunetuzumab, rituximab, tocilizumab, lenalidomide, or thalidomide formulation, including Mannitol
  9. Participants unable to receive adequate prophylaxis and/or therapy for thromboembolic events (aspirin or low molecular weight heparin or direct oral anticoagulants)
  10. History of prior , except for conditions as listed below if participants have recovered from the acute side effects incurred as a result of previous therapy and only with a single occurrence of the following conditions:

    • Malignancies treated with curative intent and with no known active disease present for ≥ 2 years before enrollment
    • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
    • Adequately treated cervical carcinoma in situ without evidence of disease
    • Surgically/adequately treated low grade, early stage I, localized prostate in situ carcinoma
  11. Participants with infections requiring IV treatment with antibiotics or hospitalization (Grade 3 or 4) within the last 4 weeks prior to inclusion or known active bacterial, viral (including SARS-CoV-2), fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds),
  12. Evidence of any significant, concomitant disease that could affect compliance with the protocol or interpretation of results, including, but not limited to:

    • Significant cardiovascular disease [e.g., Objective Class C or D heart diseases (cf. Classes of Heart Failure \| American Heart Association)], myocardial infarction within the previous 6 months, unstable arrhythmia, or unstable angina)
    • Significant pulmonary disease (such as obstructive pulmonary disease or history of bronchospasm)
    • history of liver disease, including viral or other hepatitis, or cirrhosis
    • Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease. Participants with a history of stroke who have not experienced a stroke or in the past 1 year and have no residual neurologic deficits as judged by the investigator are allowed. Participants with a history of epilepsy who have had no seizures in the past 2 years with or without anti-epileptic medications can be eligible.
  13. History of confirmed progressive multifocal leukoencephalopathy (PML)
  14. Known Positive serologic test at screening
  15. Acute or chronic virus (HCV) infection Participants who are positive for HCV antibody must be negative for HCV by polymerase chain reaction (PCR) to be eligible for study participation.
  16. Known or suspected history of hemophagocytic lymphohistiocytosis
  17. Known or suspected chronic active Epstein-Barr virus (EBV) infection within the last 4 weeks prior to inclusion
  18. History of erythema multiforme, Grade ≥3 rash, or blistering following prior treatment with immunomodulatory derivatives
  19. History of interstitial lung disease (ILD), drug-induced pneumonitis, and pneumonitis
  20. Active autoimmune disease requiring treatment
  21. History of autoimmune disease, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis; except:

    • Participants with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible.
    • Participants with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.
    • Patients with a history of disease-related immune thrombocytopenic purpura or autoimmune hemolytic anemia may be eligible
    • Participants with a remote history of, or well-controlled autoimmune disease, with a treatment-free interval from immunosuppressive therapy for 12 months may be eligible after review and discussion with the Medical Monitor.
  22. Recent major surgery with risk of bleeding within 4 weeks prior to first study treatment administration (C1D1)
  23. History of solid organ transplantation
  24. Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes an individual's safe participation in and completion of the study
  25. Person deprived of his/her liberty by a judicial or administrative decision
  26. Person hospitalized without consent
  27. Adult person under legal protection
  28. Adult person unable to provide because of intellectual impairment, any serious medical condition, laboratory abnormality or psychiatric illness
  29. Participant unable to receive at least one of the three regimens of the comparator arm. As in usual practice, physician has to verify the absence of to the use of the drugs, hypersensitivity, and to take into account the lymphoma history and previous treatment scheme used
  30. Suspicion or clinical evidence of transformed lymphoma at enrollment by investigator assessment (e.g. very high SUV (SUV > 20 or double compared to SUV of other lesions) in at least one lesion that was not biopsied, and discordant with SUV of biopsied lesion, LDH > 2.5 in a context of rapidly progressive disease, etc). Please contact the Coordinating Investigators / Sponsor to discuss such cases or if there is any doubt before considering enrollment.
  31. Uncontrolled symptomatic pleural or serous effusion requiring urgent treatment within 48 hours (participants with controlled disease after adequate pleural/serous drainage and/or effective pleurX™ or similar system are eligible only if control system is in place before randomization).
  32. Uncontrolled symptomatic ureterohydronephrosis resulting in renal failure (participants with adequate management i.e. ureteral catheter or double J stent allowing renal failure control are eligible only if control system is in place before randomization).
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    Arm 1: Mosunetuzumab and Lenalidomide

    * Mosunetuzumab will be administered SC (21 days first cycle, then 28 days next cycles) * C1 (21-days cycle): step-up dosing schedule 5 mg Day 1, 45 mg on Day 8 and 45 mg Day 15 * C2 to C12: 45 mg D1 28-days cycles * Lenalidomide PO starting dose is based on patient's creatinine clearance from Day 1 to Day 21 from cycles C2 to C6 (cycles of 28 days)

    Drug: Mosunetuzumab (SC) · Drug: Lenalidomide

  • Active comparator
    Arm 2: Rituximab-Lenalidomide (28-days cycles)

    * Rituximab\* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2-12 * Lenalidomide PO starting dose is based on patient's creatinine clearance, D1-21 from cycle 1 to cycle 6

    Drug: Rituximab (R) · Drug: Lenalidomide

  • Active comparator
    Arm 3: Rituximab-Bendamustine (28-days cycles)

    * Rituximab\* 375 mg/m2 intravenously at cycle 1 Day 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2 to 6\*\* (28-days cycles) and then at D1 of three additional 56-days cycles (C7 to C9). \*\*For patients in complete response (CR) at 3 cycles, if Bendamustine is stopped, then Rituximab should also be omitted for C5 and C6. * Bendamustine IV 70 or 90 mg/m² (according to the investigator's judgment) D1 and D2/28 days x 6 cycles 28 days cycles). For patients in complete response (CR) at 3 cycles, Bendamustine and Rituximab could be stopped after 4 cycles at investigator discretion

    Drug: Rituximab (R) · Drug: Bendamustine

  • Active comparator
    Arm 4: Rituximab-CHOP (21-days cycles)

    * Rituximab\* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2 to 6 (21-days cycles), and then at D1 of three additional 56-days cycles (C7 to C9) * CHOP, IV standard dose from cycle 1 to 6

    Drug: Rituximab (R) · Drug: CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)

Interventions

  • DrugMosunetuzumabStudies of MosunetuzumabMosunetuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    ○ Mosunetuzumab will be administered SC (21 days first cycle, then 28 days next cycles) * C1 (21-days cycle): step-up dosing schedule 5 mg Day 1, 45 mg on Day 8 and 45 mg Day 15 * C2 to C12: 45 mg D1 28-days cycles

    Also known as: Mosunetuzumab

  • DrugRituximabStudies of RituximabRituximab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Rituximab\* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2-12

    Also known as: Rituximab

  • ○ Bendamustine IV 70 or 90 mg/m² (according to the investigator's judgment) D1 and D2/28 days x 6 cycles 28 days cycles). For patients in complete response (CR) at 3 cycles, Bendamustine and Rituximab could be stopped after 4 cycles at investigator discretion

  • DrugVincristineStudies of VincristineVincristine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    CHOP, IV standard dose from cycle 1 to 6

    Also known as: CHOP

  • Cycles 2 to 6 (28-day cycles): starting dose is based on patient's creatinine clearance, from day 1 to day 21, once a day, rest period from day 22 to day 28

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) as determined by investigator

    according to Lugano criteria 2014

    Time frame: After 122 events = approximately 4.5 years and after 163 events = approximately 6.5 years (event = progression or death)

Secondary outcomes

  1. Complete Response rate (CR) as determined by investigator (CR24)

    according to Lugano criteria 2014

    Time frame: 2 years

  2. Complete response rate (CR) by blinded central review (CR24)

    based on PET result according to Lugano Criteria 2014

    Time frame: 2 years

  3. Overall response rate (ORR) as determined by investigator

    according to Lugano Criteria 2014

    Time frame: 6 months for patients with Mosunetuzumab-Lenalidomide, Rituximab-Lenalidomide or R-CHOP, 3 months for patients with Rituximab-bendamustine

  4. Overall response rate (ORR) as determined by investigator

    according to Lugano Criteria 2014

    Time frame: 12 months

  5. Overall response rate (ORR) as determined by investigator

    according to Lugano Criteria 2014

    Time frame: 24 months

  6. Overall response rate (ORR) as determined by investigator

    according to Lugano Criteria 2014

    Time frame: 36 months

  7. Overall response rate (ORR) as determined by investigator

    according to Lugano Criteria 2014

    Time frame: 48 months

  8. Overall response rate (ORR) as determined by investigator

    according to Lugano Criteria 2014

    Time frame: 60 months

  9. Overall response rate (ORR) by blinded central review

    based on PET result according to Lugano Criteria 2014

    Time frame: 6 months for patients with Mosunetuzumab-Lenalidomide, Rituximab-Lenalidomide or R-CHOP, 3 months for patients with Rituximab-bendamustine

  10. Overall response rate (ORR) by blinded central review

    based on PET result according to Lugano Criteria 2014

    Time frame: 12 months

  11. Overall response rate (ORR) by blinded central review

    based on PET result according to Lugano Criteria 2014

    Time frame: 24 months

  12. Overall response rate (ORR) by blinded central review

    based on PET result according to Lugano Criteria 2014

    Time frame: 36 months

  13. Overall response rate (ORR) by blinded central review

    based on PET result according to Lugano Criteria 2014

    Time frame: 48 months

  14. Overall response rate (ORR) by blinded central review

    based on PET result according to Lugano Criteria 2014

    Time frame: 60 months

  15. CR rate other than CR24 as determined by investigator

    according to Lugano Criteria 2014

    Time frame: 6 months for patients with Mosunetuzumab-Lenalidomide, Rituximab-Lenalidomide or R-CHOP, 3 months for patients with Rituximab-bendamustine

  16. CR rate other than CR24 as determined by investigator

    according to Lugano Criteria 2014

    Time frame: 12 months

  17. CR rate other than CR24 as determined by investigator

    according to Lugano Criteria 2014

    Time frame: 24 months

  18. CR rate other than CR24 as determined by investigator

    according to Lugano Criteria 2014

    Time frame: 36 months

  19. CR rate other than CR24 as determined by investigator

    according to Lugano Criteria 2014

    Time frame: 48 months

  20. CR rate other than CR24 as determined by investigator

    according to Lugano Criteria 2014

    Time frame: 60 months

  21. CR rate other than CR24 by blinded central review

    based on PET result according to Lugano Criteria 2014

    Time frame: 6 months for patients with Mosunetuzumab-Lenalidomide, Rituximab-Lenalidomide or R-CHOP, 3 months for patients with Rituximab-bendamustine

  22. CR rate other than CR24 by blinded central review

    based on PET result according to Lugano Criteria 2014

    Time frame: 12 months

  23. CR rate other than CR24 by blinded central review

    based on PET result according to Lugano Criteria 2014

    Time frame: 24 months

  24. CR rate other than CR24 by blinded central review

    based on PET result according to Lugano Criteria 2014

    Time frame: 36 months

  25. CR rate other than CR24 by blinded central review

    based on PET result according to Lugano Criteria 2014

    Time frame: 48 months

  26. CR rate other than CR24 by blinded central review

    based on PET result according to Lugano Criteria 2014

    Time frame: 60 months

  27. Duration of response (DOR)

    time from the first occurrence of a documented objective response to progression/relapse or death from any cause

    Time frame: 6.5 years

  28. Event-free survival (EFS)

    time from the date of randomization to the event of death of from any cause, disease progression or relapse, early discontinuation of the treatment because of any reason or first documented administration of any new anti-lymphoma treatment

    Time frame: 6.5 years

  29. Time to next anti-lymphoma treatment (TTNLT)

    time from the date of randomization to the date of first documented administration of any new anti-lymphoma treatment

    Time frame: 6.5 years

  30. Histological transformation rate

    percentage of transformation from MZL to diffuse large B-cell lymphoma

    Time frame: 6.5 years

  31. Safety: incidence and severity of Adverse Events (AE), of Serious Adverse Events (SAE), of Cytokine Release Syndrome (CRS), of AE grade 3 or 4 of study-drug_related events, incidence of Death and Secondary Primary Malignancies

    Safety described according to actual treatment arm received

    Time frame: 6.5 years

  32. Tolerability : number of dose interruptions, dose reductions, and dose intensity, and study treatment discontinuation because of adverse events

    Tolerability described according to actual treatment arm received

    Time frame: 6.5 years

  33. Health related quality of life as measured by the EQ-5D-5L

    described by domains (Mobility, Self-care, Usual activities, Pain/Discomfort and Anxiety/Depression) and with the global score

    Time frame: 7 months

  34. Health related quality of life as measured by the EQ-5D-5L

    described by domains (Mobility, Self-care, Usual activities, Pain/Discomfort and Anxiety/Depression) and with the global score

    Time frame: 12 months

  35. Health related quality of life as measured by the EQ-5D-5L

    described by domains (Mobility, Self-care, Usual activities, Pain/Discomfort and Anxiety/Depression) and with the global score

    Time frame: 24 months

07

Study locations

26 of 48 sites recruiting
  • INSTITUT JULES BORDET - Service Hématologie
    Anderlecht, 1070, Belgium
    Not yet recruiting
  • UNIVERSITE CATHOLIQUE DE LOUVAIN SAINT-LUC - Service Hématologie
    Brussels, 1200, Belgium
    Not yet recruiting
  • UNIVERSITAIR ZIEKENHUIS GENT - Service Hématologie
    Ghent, 9000, Belgium
    Recruiting
  • CHU UCL NAMUR - SITE GODINNE - Service Hématologie
    Yvoir, 5530, Belgium
    Not yet recruiting
  • CHU de Nancy - Brabois
    Nancy, France, France
    Recruiting
    • Pierre FEUGIER, MD · Contact
  • CHU d'Amiens
    Amiens, France
    Recruiting
    • Caroline DELETTE, MD · Contact
  • CH d'Avignon - Hopital Henri Duffaut
    Avignon, France
    Recruiting
    • Hacene ZERAZHI, MD · Contact
  • CH de la Côte Basque - Hôpital de Bayonne
    Bayonne, France
    Recruiting
    • Sophie BERNARD, MD · Contact
  • CHRU Besançon - Hôpital Minjoz
    Besançon, France
    Recruiting
    • Adrien CHAUCHET, MD · Contact
  • Institut Bergonié
    Bordeaux, France
    Recruiting
    • Fontanet BIJOU, Pr · Contact
  • Chu Estaing
    Clermont-Ferrand, France
    Recruiting
    • Olivier Tournilhac, MD · Contact
  • CHU Henri Mondor
    Créteil, France
    Recruiting
    • Corinne Haioun · Contact
  • CHU de Dijon
    Dijon, France
    Recruiting
    • Olivier CASASNOVAS, MD · Contact
  • CHU de Grenoble - Hôpital Albert Michallon
    La Tronche, France
    Recruiting
    • Sylvain CARRAS, MD · Contact
  • CHRU de LILLE - Claude Huriez
    Lille, France
    Recruiting
    • Franck MORSHHAUSER, Pr · Contact
  • Institut Paoli Calmette
    Marseille, France
    Recruiting
    • Aude Collignon, MD · Contact
  • CH Saint-Eloi
    Montpellier, France
    Recruiting
    • Guillaume CARTRON, MD · Contact
    • Guillaume CARTRON, MD · Principal investigator
  • Centre Catherine de Sienne
    Nantes, France
    Recruiting
    • Nadine Morineau, MD · Contact
  • CHU de Nantes - Hôtel Dieu
    Nantes, France
    Recruiting
    • Béatrice MAHE, MD · Contact
  • Centre Antoine Lacassagne
    Nice, France
    Recruiting
    • Fréderic PEYRADE, Pr · Contact
  • CHU de Nice
    Nice, France
    Recruiting
    • Edmond CHICHE, MD · Contact
  • CHR d'Orléans
    Orléans, France
    Recruiting
    • Marlène OCHMANN, MD · Contact
  • APHP - Hôpital Saint Louis
    Paris, France
    Recruiting
    • Catherine Thieblemont, Pr · Contact
  • CHU Lyon Sud
    Pierre-Bénite, France
    Recruiting
    • Emmanuel BACHY, MD · Contact
  • CHU de Rennes - Hôpital de Pontchaillou
    Rennes, France
    Recruiting
    • Roch HOUOT, MD · Contact
  • Centre Henri Becquerel
    Rouen, France
    Recruiting
    • Fabrice JARDIN, Pr · Contact
  • Institut de Cancérologie de la Loire Lucien Neuwirth
    Saint-Priest-en-Jarez, France
    Recruiting
    • Ludovic FOUILLET, MD · Contact
  • KLINIKUM ST. MARIEN AMBERG - Hämatologie/Onkologie
    Amberg, Germany
    Not yet recruiting
  • Helios Klinikum Berlin-Buch - Klinik für Hämatologie und Stammzelltransplantation
    Berlin, Germany
    Not yet recruiting
  • UNIVERSITAETSKLINIKUM SCHLESWIG-HOLSTEIN - Med. Klinik II - Hämatologie und Onkologie
    Kiel, Germany
    Not yet recruiting
  • KLINIKUM DER STADT LUDWIGSHAFEN - Hämatologie
    Ludwigshafen, Germany
    Recruiting
  • UNIVERSITATSKLINIKUM REGENSBURG - Klinik für Innere Medizin III
    Regensburg, Germany
    Not yet recruiting
    • Stephanie MAYER, MD · Contact
  • ROBERT BOSCH KRANKENHAUS - Hämatologie, Onkologie und Palliativmedizin
    Stuttgart, Germany
    Not yet recruiting
  • MUTTERHAUS DER BORROMAERINNEN - Hämatologie
    Trier, Germany
    Not yet recruiting
  • UNIV KLINIKUM ULM - INNERE MEDIZIN III - Hämatologie
    Ulm, Germany
    Not yet recruiting
  • UNIVERSITY WURZBURG - Hämatologie
    Würzburg, Germany
    Not yet recruiting
  • POLICLINICO SANT'ORSOLA-MALPIGHI - Ematologia
    Bologna, Italy
    Not yet recruiting
    • Pier Luigi ZINZANI, Prof. · Contact
  • INSTITUTO ONCOLOGICO VENETO I.R.C.C.S - Ematologia
    Castelfranco Veneto, Italy
    Not yet recruiting
  • AZIENDA OSPEDALIERA S. CROCE E CARLE CUNEO - Ematologia
    Cuneo, Italy
    Not yet recruiting
  • SAPIENZA UNIVERSIT DI ROMA - POLO PONTINO - OSPEDALE S. MARIA GORETTI LATINA - UOC Ematologia
    Latina, Italy
    Not yet recruiting
  • OSPEDALE VITO FAZZI LECCE - Hematologia
    Lecce, Italy
    Not yet recruiting
  • OSPEDALE SAN RAFFAELE - Unità di Ricerca Clinica Linfomi Dipartimento di Onco-ematologia
    Milan, Italy
    Not yet recruiting
  • AZIENDA OSPEDALIERO UNIVERITARIA DI MODENA - Ematologia
    Modena, Italy
    Not yet recruiting
  • POLICLINICO SAN MATTEO - SC Ematologia
    Pavia, Italy
    Not yet recruiting
    • Luca ARCAINI, MD · Contact
  • OSPEDALE S. MARIA DELLE CROCI - Dipartimento di Oncologia ed Ematologia
    Ravenna, Italy
    Not yet recruiting
  • AOU CITTA DELLA SALUTE E DELLA SCIENZA DI TORINO - Ematologia
    Torino, Italy
    Not yet recruiting
  • OSPEDALE MAGGIORE ASUGI - UCO Ematologia
    Trieste, Italy
    Not yet recruiting
  • INSTITUTO PORTUGUES DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL - Departamento Hematologia
    Lisbon, 1099, Portugal
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2023 (actual). Primary completion is estimated for Sep 2027, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2023
First posted
Aug 23, 2023
StartActual
Sep 5, 2023
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2032
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06006117
Lead sponsor
The Lymphoma Academic Research Organisation
Responsible party
Sponsor
First posted
Aug 23, 2023
Start date
Sep 5, 2023
Primary completion
Sep 2027 (estimated)
Completion
Sep 2032 (estimated)
Last update
Jun 15, 2026

Study contacts

Christine STEPHAN
Contact
christine.stephan@lysarc.org
04 72 66 38 76
Catherine THIEBLEMONT, Pr
principal investigator · Lymphoma Study Association
Sylvain CARRAS
principal investigator · Lymphoma Study Association

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mosunetuzumab · Lenalidomide

Start the discussion